This article is more than 5 years old. Information may no longer be current.
RXi Pharmaceuticals reports pipeline developments, Q1 financial results
Click Here to Manage Email Alerts
RXi Pharmaceuticals Corp. recently announced its first-quarter financial results, as well as clinical updates.
For the quarter ended March 31, 2015, RXi reported cash and cash equivalents of approximately $6.6 million, compared with $8.5 million on Dec. 31, according to a company press release.Toxicology studies required for the company’s investigational new ophthalmology drug, subject-related fees for the company’s three ongoing phase 2a clinical trials and expenses related to the close of its Samcyprone license agreement in February 2015 were behind the increase in research and development costs from the previous quarter, according to the release.
“The exclusive license of our [self-delivering] sd-rxRNA technology to Mirlmmune for ex vivo cell-based cancer immunotherapies not only provides the potential for long-term financial return, it also highlights the potential therapeutic development opportunities for our proprietary platform,” Geert Cauwenbergh, PhD, MedSc, president and CEO of RXi, said in the release. “Furthermore, the global license agreement of Samcyprone now allows us to drive this program forward and further broadens our clinical pipeline.”
Additionally, top-line results from the company’s first phase 2a trial 3 months after scar-revision surgery have offered guidance for RXi’s ongoing and future clinical development and strategy for RXI-109, Cauwenbergh said.
Based on early results of the phase 2a study, the company is implementing an optimized dosing regimen in the ongoing study for RXI-109 in which therapy initiated 2 weeks after scar-revision surgery will be compared with treatment initiation immediately following surgery, according to the release.
Samcyprone, a proprietary topical formulation of diphenylcyclopropenone, is being evaluated for the treatment of warts, alopecia areata and cutaneous metastases of malignant melanoma.
Data on RXi’s proprietary self-delivering RNAi (sd-rxRNA) compounds developed to target tyrosinase and collagenase, which led to a visible reduction of pigmentation of melanocytes in a 3-D tissue culture model of human epidermis, were presented at the Society for Investigative Dermatology Annual Meeting on May 6-9, according to the press release.
Reference: www.rxipharma.com.